Why BGPT?
logo

Evidence for paper review

Inspect each claim in a paper against the experiments and reported results that support it, including limitations and provenance.Know what the science actually supports before you trust the answer.

Press Enter ↵ to review



    Explore by Goal









     Quick Explanation


    Key takeaway: The review argues that gut microbiota composition can correlate with— and in some preclinical models causally influence—responses and immune-related toxicity to immune checkpoint inhibitors (ICIs), motivating microbiome-informed prognostic/stratification efforts, but also emphasizing major variability and unresolved mechanisms.



     Long Explanation


    Paper Review (Full-text basis): Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications

    Published in Future Oncology (26 Feb 2020). DOI: 10.2217/fon-2019-0783
    Authors (as extracted from provided paper text): Deniz Can Guven; Burak Yasin Aktas; Cem Simsek; Sercan Aksoy.

    Timeline of key “microbiota ↔ ICI” anchor experiments explicitly mentioned in the review

    Note: This is a timeline of anchor studies cited in the review text, not a comprehensive bibliometric timeline.
    Source for each timeline point is the review’s narrative description of these anchor studies.

    Mechanistic structure proposed in the review (microbiota ↔ immune checkpoint blockade)

    This is a faithful conceptual re-organization of what the review claims, not new mechanistic inference.
    Inputs that perturb microbiota
    Antibiotics, diet, age/sex, and other medication/lifestyle factors drive microbiota variability.
    Microbiota state
    Firmicutes/Bacteroidetes and specific genera/taxa are discussed as correlates of immune “set points”.
    Immune effects in host
    Modulation of antigen presentation and T-cell differentiation/activation is described, shaping response and toxicity risk.
    ICI outcomes
    Preclinical evidence: antibiotics/germ-free status can impair ICI effects; transfer can rescue. Human evidence: baseline taxa associate with response and colitis.
    Concept nodes are directly anchored in the review’s discussion of bidirectionality and influencing factors.

    Evidence classes emphasized in the review

    The review integrates multiple evidence types; however, it also emphasizes heterogeneity and uncertainty.
    Evidence class (as discussed) What it supports (review claim) Main limitation (review claim)
    Preclinical perturbation + transfer (antibiotics/germ-free vs recolonization/FMT) Microbiota can causally influence ICI efficacy and immune activation phenotypes Animal-to-human generalization remains uncertain; mechanistic mapping is incomplete
    Human baseline stool microbiome associations Specific taxa profiles correlate with ICI response and/or immune-related adverse events like colitis Across-study variability is high; confounders (diet, meds including antibiotics, age/sex) complicate biomarker standardization
    Antibiotic exposure observational signals Antibiotic use around ICI initiation often associates with worse outcomes Retrospective, indirect; some contradictory findings exist; timing/dose/type of antibiotics varies
    Multi-omic augmentation (metatranscriptomics/metabolomics) Improves mechanistic interpretability and may help build multi-omic prognostic panels Not yet standardized; still emerging compared to taxonomic-only approaches
    Microbiota modulation trials (FMT/diet/postbiotics) Motivates therapeutic strategies to improve efficacy/toxicity balance No completed Phase III studies; human trials heterogeneous; safety/standardization challenges
    All table items summarize claims and limitations discussed in the review.

    Skeptical critique (known/assumed/uncertain)

    What appears comparatively “strong” within the review’s own evidence framing
    • The review argues that antibiotics/germ-free status can impair ICI efficacy in preclinical models and that transfer can partially restore effects—this is qualitatively stronger than correlation alone.
    • The review also emphasizes that microbiota composition associates with both response and toxicity phenotypes in human studies (e.g., colitis risk), and sometimes includes immune correlates (T-cell phenotypes, regulatory mechanisms).
    Where the review flags uncertainty / heterogeneity
    • Signature instability: the review repeatedly notes that different studies report different taxa associated with response/toxicity, making it hard to define robust universal prognostic markers.
    • Confounding & measurement: microbiota is labile and affected by age/sex, diet, and medications; antibiotics are especially hard to control in retrospective human analyses.
    • Contradictory observational findings: the review describes that most antibiotic studies suggest negative associations, but some reports show no significant difference, indicating that effect sizes may depend on patient subgroups, antibiotic timing/type, and study design.
    What would most efficiently disprove or substantially revise the review’s core claims
    • Independent prospective cohorts that fail to reproduce baseline microbiome associations with response and/or colitis risk across standardized sampling and analysis workflows (reducing the chance that signatures are batch/artifact-driven).
    • Mechanistic experiments showing that changing candidate taxa does not reproduce the predicted immune phenotype shifts (response enhancement or toxicity reduction) when controlling for broader community context.
    • Clinical intervention evidence where microbiota modulation strategies yield no consistent improvement and/or introduce net harms—especially given the risk/safety and heterogeneity concerns raised for FMT and other modulation.

    Author Reviews (open BGPT deep dives)

    If you want, run BGPT’s AI Scientist agent to re-synthesize the review and extract a tighter “mechanism → evidence → confidence” map.


    Feedback:    

    Updated: April 02, 2026

     BGPT Paper Review


    Study Novelty

    70%

    The paper synthesizes a fast-moving preclinical→human translation area (microbiota–ICI bidirectionality), but does not appear to introduce a brand-new primary dataset; novelty is mainly integrative and conceptual for prognostic/therapeutic implications.


    Scientific Quality

    70%

    Scientific quality is reasonably strong as a structured synthesis, but—as a review—it inherits risks from underlying study heterogeneity (methods, populations, confounding) and cannot resolve causality by itself. The review’s own discussion highlights heterogeneity and the need for more robust validation, limiting definitive clinical claims.


    Study Generality

    60%

    The topic is broadly general (microbiota and cancer immunotherapy across tumor types), but the translational arguments are heavily anchored in melanoma/NSCLC exemplars and in specific classes of evidence, limiting universality across cancers and ICI combinations.


    Study Usefulness

    80%

    Useful as a scientific map: it organizes evidence into prognostic markers, therapeutic implications, antibiotic confounding, and future multi-omic stratification directions.


    Study Reproducibility

    60%

    As a review, it is reproducible in concept, but reproducibility of its implied ‘biomarker rules’ is limited because the review highlights inconsistent taxa associations across studies and large methodological variability.


    Explanatory Depth

    70%

    Moderate mechanistic depth: it discusses immune-cell/tumor-microenvironment mechanisms at a high level and includes examples of immune phenotype associations, but it also explicitly states that precise mechanisms and involved microorganisms remain undefined.


    🎁 Authors: Collect 197 Free Science Tokens (≈ $19.7 USD)

    Claim My Author Tokens

    Use for 49 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $19.7 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    Build a study-type evidence matrix from the review, then generate a taxon-vs-outcome robustness heatmap by extracting only explicitly named associations and their study contexts from the paper text.



     Hypothesis Graveyard


    “A single genus (e.g., Akkermansia or Bacteroides) universally predicts response across all cancers/ICIs.” This is weakened by the review’s own emphasis that most studies report different microbiota patterns across methodologies and populations.


    “Antibiotics impair ICI efficacy only through microbiota depletion; host factors are irrelevant.” This is undermined because the review highlights multiple microbiota perturbation sources (diet, age/sex, other medications) and that mechanistic pathways are not fully defined.

     Science Art


    Paper Review: Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending